- Home
- HCA vs BMY Comparison
HCA vs BMY Comparison
Compare HCA & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | BMY |
|---|---|---|
| Founded | 1968 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.1B | 95.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | BMY |
|---|---|---|
| Price | $481.47 | $51.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $463.06 | $55.09 |
| AVG Volume (30 Days) | 1.3M | ★ 15.1M |
| Earning Date | 01-23-2026 | 10-30-2025 |
| Dividend Yield | 0.61% | ★ 4.84% |
| EPS Growth | ★ 15.74 | N/A |
| EPS | ★ 25.82 | 2.97 |
| Revenue | ★ $74,372,000,000.00 | $48,034,000,000.00 |
| Revenue This Year | $8.37 | $0.23 |
| Revenue Next Year | $4.46 | N/A |
| P/E Ratio | $18.15 | ★ $17.24 |
| Revenue Growth | ★ 6.82 | 1.26 |
| 52 Week Low | $289.98 | $42.52 |
| 52 Week High | $520.00 | $63.33 |
Technical Indicators
Market Signals| Indicator | HCA | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 63.60 |
| Support Level | $466.22 | $50.33 |
| Resistance Level | $491.24 | $52.51 |
| Average True Range (ATR) | 12.02 | 1.16 |
| MACD | -4.39 | 0.16 |
| Stochastic Oscillator | 25.86 | 80.62 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.